John D Cramer1, Sedona E Speedy2, Robert L Ferris3, Alfred W Rademaker4, Urjeet A Patel1, Sandeep Samant1. 1. Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Northwestern University Feinberg School of Medicine, Chicago, Illinois. 3. Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 4. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Abstract
BACKGROUND: The National Quality Forum has endorsed quality-improvement measures for multiple cancer types that are being developed into actionable tools to improve cancer care. No nationally endorsed quality metrics currently exist for head and neck cancer. METHODS: The authors identified patients with surgically treated, invasive, head and neck squamous cell carcinoma in the National Cancer Data Base from 2004 to 2014 and compared the rate of adherence to 5 different quality metrics and whether compliance with these quality metrics impacted overall survival. The metrics examined included negative surgical margins, neck dissection lymph node (LN) yield ≥ 18, appropriate adjuvant radiation, appropriate adjuvant chemoradiation, adjuvant therapy within 6 weeks, as well as overall quality. RESULTS: In total, 76,853 eligible patients were identified. There was substantial variability in patient-level adherence, which was 80% for negative surgical margins, 73.1% for neck dissection LN yield, 69% for adjuvant radiation, 42.6% for adjuvant chemoradiation, and 44.5% for adjuvant therapy within 6 weeks. Risk-adjusted Cox proportional-hazard models indicated that all metrics were associated with a reduced risk of death: negative margins (hazard ratio [HR] 0.73; 95% confidence interval [CI], 0.71-0.76), LN yield ≥ 18 (HR, 0.93; 95% CI, 0.89-0.96), adjuvant radiation (HR, 0.67; 95% CI, 0.64-0.70), adjuvant chemoradiation (HR, 0.84; 95% CI, 0.79-0.88), and adjuvant therapy ≤6 weeks (HR, 0.92; 95% CI, 0.89-0.96). Patients who received high-quality care had a 19% reduced adjusted hazard of mortality (HR, 0.81; 95% CI, 0.79-0.83). CONCLUSIONS: Five head and neck cancer quality metrics were identified that have substantial variability in adherence and meaningfully impact overall survival. These metrics are appropriate candidates for national adoption. Cancer 2017;123:4372-81.
BACKGROUND: The National Quality Forum has endorsed quality-improvement measures for multiple cancer types that are being developed into actionable tools to improve cancer care. No nationally endorsed quality metrics currently exist for head and neck cancer. METHODS: The authors identified patients with surgically treated, invasive, head and neck squamous cell carcinoma in the National Cancer Data Base from 2004 to 2014 and compared the rate of adherence to 5 different quality metrics and whether compliance with these quality metrics impacted overall survival. The metrics examined included negative surgical margins, neck dissection lymph node (LN) yield ≥ 18, appropriate adjuvant radiation, appropriate adjuvant chemoradiation, adjuvant therapy within 6 weeks, as well as overall quality. RESULTS: In total, 76,853 eligible patients were identified. There was substantial variability in patient-level adherence, which was 80% for negative surgical margins, 73.1% for neck dissection LN yield, 69% for adjuvant radiation, 42.6% for adjuvant chemoradiation, and 44.5% for adjuvant therapy within 6 weeks. Risk-adjusted Cox proportional-hazard models indicated that all metrics were associated with a reduced risk of death: negative margins (hazard ratio [HR] 0.73; 95% confidence interval [CI], 0.71-0.76), LN yield ≥ 18 (HR, 0.93; 95% CI, 0.89-0.96), adjuvant radiation (HR, 0.67; 95% CI, 0.64-0.70), adjuvant chemoradiation (HR, 0.84; 95% CI, 0.79-0.88), and adjuvant therapy ≤6 weeks (HR, 0.92; 95% CI, 0.89-0.96). Patients who received high-quality care had a 19% reduced adjusted hazard of mortality (HR, 0.81; 95% CI, 0.79-0.83). CONCLUSIONS: Five head and neck cancer quality metrics were identified that have substantial variability in adherence and meaningfully impact overall survival. These metrics are appropriate candidates for national adoption. Cancer 2017;123:4372-81.
Authors: Evan M Graboyes; Chanita Hughes Halbert; Hong Li; Graham W Warren; Anthony J Alberg; Elizabeth A Calhoun; Brian Nussenbaum; Courtney H Marsh; Jessica McCay; Terry A Day; John M Kaczmar; Anand K Sharma; David M Neskey; Katherine R Sterba Journal: JCO Oncol Pract Date: 2020-08-27
Authors: Tyler A Janz; Joanne Kim; Elizabeth G Hill; Katherine Sterba; Graham Warren; Anand K Sharma; Terry A Day; Chanita Hughes-Halbert; Evan M Graboyes Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-12-01 Impact factor: 6.223
Authors: Helmneh M Sineshaw; Mark A Ellis; K Robin Yabroff; Xuesong Han; Ahmedin Jemal; Terry A Day; Evan M Graboyes Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-03-01 Impact factor: 6.223
Authors: Dylan A Levy; Hong Li; Katherine R Sterba; Chanita Hughes-Halbert; Graham W Warren; Brian Nussenbaum; Anthony J Alberg; Terry A Day; Evan M Graboyes Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-05-01 Impact factor: 6.223
Authors: Robert L Ferris; Yael Flamand; F Christopher Holsinger; Gregory S Weinstein; Harry Quon; Ranee Mehra; Joaquin J Garcia; Michael L Hinni; Neil D Gross; Erich M Sturgis; Umamaheswar Duvvuri; Eduardo Méndez; John A Ridge; J Scott Magnuson; Kerry A Higgins; Mihir R Patel; Russel B Smith; Daniel W Karakla; Michael E Kupferman; James P Malone; Benjamin L Judson; Jeremy Richmon; Jay O Boyle; Rodrigo Bayon; Bert W O'Malley; Enver Ozer; Giovana R Thomas; Wayne M Koch; R Bryan Bell; Nabil F Saba; Shuli Li; Elin R Sigurdson; Barbara Burtness Journal: Oral Oncol Date: 2020-07-14 Impact factor: 5.337
Authors: Evan M Graboyes; Katherine R Sterba; Hong Li; Graham W Warren; Anthony J Alberg; Elizabeth A Calhoun; Brian Nussenbaum; Jessica McCay; Courtney H Marsh; Nosayaba Osazuwa-Peters; David M Neskey; John M Kaczmar; Anand K Sharma; Jennifer Harper; Terry A Day; Chanita Hughes-Halbert Journal: JCO Oncol Pract Date: 2021-03-10